Ascendis Pharma A (ASND) EBITDA (2014 - 2026)

Ascendis Pharma A has reported EBITDA for 13 years, with the latest figure at $29.0 million in Q1 2026.

• Quarterly EBITDA rose 126.5% year-over-year to $29.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.5 million (down 100.0% YoY) and the FY2025 annual result came in at -$158.6 million, up 46.75% from the prior year.
• EBITDA grew to $29.0 million in Q1 2026 per ASND's latest filing, from $11.5 million in the prior quarter.
• Over five years, EBITDA peaked at $409.3 billion in Q4 2024 and troughed at -$154.2 million in Q1 2023.
• A 5-year average of $24.0 billion and a median of -$109.6 million in 2025 frame the typical range for EBITDA.
• The sharpest annual moves came in 2024 and 2025: EBITDA soared 1039121.01% in 2024, then sank 105.32% in 2025.
• Over 5 years, EBITDA stood at -$150.4 million in 2022, then surged by 73.8% to -$39.4 million in 2023, then jumped by 1039121.01% to $409.3 billion in 2024, then slumped by 100.0% to $11.5 million in 2025, then surged by 152.17% to $29.0 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $29.0 million, $11.5 million, and $12.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.